Abstract
Dermatomyositis (DM) is a rare chronic autoimmune condition with characteristic skin manifestations and progressive proximal muscle weakness. Although treatments such as glucocorticoids and other immunosuppressive or immunomodulatory therapies including immunoglobulins are used, evidence supporting their efficacy in DM is limited. The ProDERM study aimed to investigate the efficacy and safety/tolerability of intravenous immunoglobulins (IVIG - Octagam 10%) in patients with DM in a prospective, parallel group, double-blind, randomized, placebo-controlled, international multicenter, phase III study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
